Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front Med Chin    2009, Vol. 3 Issue (1) : 91-95     DOI: 10.1007/s11684-009-0011-z
Experimental study on the efficacy of Fuganling granula on protecting against immunological hepatic injury
Yanli LIU, Rong LIU, Cheng ZHEN, Quanfang GUO, Liping WU, Zhaoxi DING, Yushun BI, Zhiyu LIU()
Department of Anatomy, Shandong University School of Medicine, Jinan 250012, China
Download: PDF(196 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

To study the efficacy of Fuganling granula (FGL, 复肝灵颗粒) in treating mouse immunological hepatic injury that was caused by Bacille Calmette Guerin (BCG) and lipopolysaccharide (LPS), a total of 60 mice were adopted, among which, 50 mice were given intraperitoneal injection with BCG and LPS to establish an immunological liver injury model and then were randomly divided into 5 groups (10 mice/group): 4 groups received treatment of FGL orally at the doses of 100 mg/kg (high-dosage), 50 mg/kg (middle-dosage), 25 mg/kg (low-dosage) and bifendate orally at the dose of 80 mg/kg, respectively. One group was treated with distilled water orally. The remaining 10 mice were given distilled water intraperitoneally as the normal control group. The indices of thymus, liver and spleen, and the activities of the alanine aminotransferase (ALT), aspartate aminotransferase (AST) in the serum were detected. Compared to the normal rat, the model group’s thymus index decreased significantly. The liver index and spleen index increased significantly. The activities of serum ALT and AST increased significantly (all P< 0.01). Compared to the model control group, the group treated with FGL in high-dosage, middle-dosage or low-dosage can decrease the activities of ALT and AST and the group treated with FGL in high-dosage and middle-dosage can increase the thymus index significantly (P< 0.01). This experiment established the immunological liver injury model successfully and found that FGL has a remarkably protective effect on this kind of immunological hepatic injury.

Keywords Fuganling granula      immunological liver injury      bacille calmette guerin      lipopolysaccharide      mice     
Corresponding Authors: LIU Zhiyu,   
Issue Date: 05 March 2009
URL:     OR
groupsndose/mg·kg-1liver index/mg·g-1spleen index/mg·g-1thymus index/mg·g-1
normal control10distilled water46.81 ± 4.233.78 ± 0.803.36 ± 0.74
model control10distilled water62.35 ± 3.82**7.21 ± 1.89**2.43 ± 0.60**
bifendate108060.43 ± 6.20##7.11 ± 1.28#2.84 ± 0.57##
FGL large-dosage1010054.82 ± 5.89##??6.50 ± 1.24##?2.96 ± 0.50##
FGL middle-dosage105055.56 ± 6.00##??6.68 ± 1.91##?2.82 ± 0.44##
FGL low-dosage102556.88 ± 3.26##??7.02 ± 1.34##2.68 ± 0.52##
Tab.1  Effect of FGL on the indices of thymus, liver and spleen in immunological liver injury model
groupsndose /mg·kg-1ALT/U·L-1AST/U·L-1
normal control10distilled water35 ± 12158 ± 37
model control10distilled water168 ± 123**234 ± 75**
bifendate108065 ± 12??179 ± 35??
FGL large-dosage1010069 ± 98##168 ± 51##
FGL middle-dosage105078 ± 52##179 ± 34##
FGL low-dosage102584 ± 65##186 ± 46##
Tab.2  Effect of FGL on activities of ALT, AST in immunological mouse liver injury model
groupsndose /mg·kg-1MDA/nmol·ggw-1P
normal control10distilled water1.77 ± 0.53&lt; 0.01
model control10distilled water4.83 ± 1.61
bifendate10802.81 ± 1.07&lt; 0.01
FGL large-dosage101002.54 ± 1.54**&lt; 0.01
FGL middle-dosage10502.70 ± 1.45**&lt; 0.01
FGL low-dosage10252.74 ± 0.75**&lt; 0.01
Tab.3  Effect of FGL on contents of peroxidative product MDA in immunological liver injury model
Fig.1  Hepatic pathological change after treatment (× 400). (a) The normal structure of liver; (b) and (c) the injury liver tissue induced by BCG + LPS; (d) and (e) the structure of liver after treated with high and medium dose of FGL.
1 Gong N M, Wei L W, Sun P, Bi Y S, Liu Z Y. Experiment study on the effect of Fuganling on liver injury induced by CCl4 in rabbit. Shandong Daxue Xuebao Yixuebao , 2006, 44(5): 460-462 (in Chinese)
2 Xu S Y, Bian R L, Chen X. Pharmacological Empirical Method. Beijing: People’s Medical Publishing House, 2002, 1346-1347 (in Chinese)
3 Liu P, Song D J. Etiopathogenesis of hepatic injury caused by drug. Ganzang , 2001, 6(1): 40-41 (in Chinese)
4 Andrade R J, Lucena M I, Santalla F. Hepatic injury associated with losartan. Ann Pharmacother , 1998, 32(12): 1371
doi: 10.1345/aph.18087a
5 Lai V, Smith A, Thorburn D, Raman V S. Severe hepatic injury and adulterated Chinese medicines. BMJ , 2006, 332(7536): 304-305
doi: 10.1136/bmj.332.7536.304-b
6 Finotto S, Siebler J, Hausding M, Schipp M, Wirtz S, Klein S, Protschka M, Doganci A, Lehr H A, Trautwein C, Khosravi-Fahr R, Strand D, Lohse A, Galle P R, Blessing M, Neurath M F. Severe hepatic injury in interleukin 18 (IL-18) transgenic mice: a key role for IL-18 in regulating hepatocyte apoptosis in vivo. Gut , 2004, 53(3): 392-400
doi: 10.1136/gut.2003.018572
7 Ma X, Gu L, Zhao J R, Lei D L, Lang S H, Ye L X, Dong L Z, Yu Y P. Reparation function of hepatic cell growth substance in experimental hepatic injury. Weishengwuxue Mianyixue Jinzhan , 2000, 28(1): 37-40 (in Chinese)
8 Wang H, Wei W, Yue L, Wang N P, Gui S Y, Wu L, Sun W Y, Xu S Y. Protective effect of total glucosides of paeony on immunological liver injury in mice induced by Bacillus Calmette-Guerin plus lipopolysaccharide. Zhongguo Yaolixue Tongbao , 2004, 20(8): 875-878 (in Chinese)
9 Xu H B, Gong Y P, Cheng J, Chu Y W, Xiong S D. CXCL16 participates in pathogenesis of immunological liver injury by regulating T lymphocyte infiltration in liver tissue. World J Gastroenterol , 2005, 11(32): 4979-4985
10 Ju C. Immunological mechanisms of drug-induced liver injury. Curr Opin Drug Discov Devel , 2005, 8(1): 38-43
11 Liu D F, Wei W, Song L H. Protective effect of paeoniflorin on immunological liver injury induced by bacillus Calmette-Guerin plus lipopolysaccharide: modulation of tumour necrosis factor-alpha and interleukin-6 MRNA. Clin Exp Pharmacol Physiol , 2006, 33(4): 332-339
doi: 10.1111/j.1440-1681.2006.04371.x
12 Li X. Curative effect and appreciation of glycyrrhizic acids drug in treating chronic virus hepatitis. Zhongguo Yaolixue Tongbao , 1999, 15(4): 383-384 (in Chinese)
13 Wu J C, Wang Z R, Wan Q H. The research of acute immunized hepat onecrosis animal model treated with the traditional Chinese medicine and anti-IL8. Suzhou Daxue XuebaoYixuebao , 2007, 27(2): 203 (in Chinese)
14 Wu J, Li L, Zou Y. Determination of carbamate insecticides in Chinese medicinal herbs by gas chromatography with a nitrogen-phosphorus detector. J AOAC Int , 2005, 88(4): 1261-1264
15 Zhu P T, Bo P, Chen X Y, Wu Y J, Chen C B, Li X M. Use W303-1A/hER-ERE-Lac Z to determine estrogenic compounds in traditional Chinese materia medica. Zhongguo Zhongyao Zazhi , 2007, 32(24): 2636-2639 (in Chinese)
16 Yance D R Jr, Sagar S M. Targeting angiogenesis with integrative cancer therapies. Integr Cancer Ther , 2006, 5(1): 9-29
doi: 10.1177/1534735405285562
17 Yang D G, Deng X, Liu Z Y. Clinical observation of the liver cirrhosis with abnormal alpha fetoprotein treated by zhengganfang. Zhongxiyi Jiehe , 2007, 5(6): 351 (in Chinese)
18 Gantner F, Leist M, Lohse A W, Germann P G, Tiegs G. Concanavalin A-induced T cell mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology , 1995, 21(1): 190
19 Yao H W, Yue L. Effect and mechanisms of FR167653, a dual inhibitor of TNF-alpha and IL-1, on BCG plus LPS induced-liver injury. Inflamm Res , 2005, 54(11): 471-477
doi: 10.1007/s00011-005-1381-6
20 Xu H B, Gong Y P, Jiang Z G, Liu R Z, Xiong S D. The role of CXCL16 in immunological liver injury induced by BCG and LPS in mice. Zhonghua Ganzangbing Zazhi , 2005, 13(4): 282-285 (in Chinese)
[1] Hongbo TANG MD, Zirong YE MM, Yuping REN MD, Zhanyong ZHU MD, Yiping WU MD, . Investigation on the mechanism of ginsenoside Rg3 in treating murine primary mammary tumor[J]. Front. Med., 2009, 3(4): 421-425.
[2] WANG Fei, DAI Yalei, XU Ting, XU Bo, WANG Kaifeng. Effect of IL-10 on formation of foam cell induced by ox-LDL[J]. Front. Med., 2008, 2(3): 298-302.
Full text